Page last updated: 2024-08-26

bosentan anhydrous and Skin Neoplasms

bosentan anhydrous has been researched along with Skin Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A1
Ballmer, A; Beith, JM; Clozel, M; Kefford, R; Kusic, R; Millward, M; Morganti, A; Nayler, O; Segal, E; Shreeniwas, R; Trotter, JM; Van Hazel, GA; Wyld, DK1

Trials

2 trial(s) available for bosentan anhydrous and Skin Neoplasms

ArticleYear
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
    Molecular cancer, 2010, Mar-30, Volume: 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides

2010
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
    Investigational new drugs, 2007, Volume: 25, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Australia; Bosentan; Endothelin Receptor Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Receptors, Endothelin; RNA, Messenger; Skin Neoplasms; Sulfonamides; Tablets; Tomography, X-Ray Computed; Treatment Outcome

2007